Rhythm Pharmaceuticals, Inc. · NASDAQ:RYTM
Garfield Alastair sold 7,763 Rhythm Pharmaceuticals, Inc. shares (Form 4)
Traded Aug 13, 2026 · Filed Aug 17, 2026
On Aug 13, 2026, Garfield Alastair (Chief Scientific Officer) sold 7,763 Rhythm Pharmaceuticals, Inc. shares at an average US$117.57 for US$913K under a trading plan, leaving 2,295 shares. Filed Aug 17, 2026 (Form 4).
- Sold
- 7,763 shares
- Price
- US$117.57 average (US$116.11 to US$119.17)
- Value
- US$913K
- Holding after
- 2,295 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Chief Scientific Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | Common Stock | Sale | 2,007 | US$116.11 | 8,051 | Direct |
| Aug 13, 2026 | Common Stock | Sale | 1,556 | US$117.08 | 6,495 | Direct |
| Aug 13, 2026 | Common Stock | Sale | 3,400 | US$118.28 | 3,095 | Direct |
| Aug 13, 2026 | Common Stock | Sale | 800 | US$119.17 | 2,295 | Direct |
Source
Related
- Rhythm Pharmaceuticals, Inc.
- Garfield Alastair
- Rhythm Pharmaceuticals, Inc. shareholders
- Form 4 · Garfield Alastair · Jul 2, 2026
- Schedule 13G · JPMorgan Chase & Co · Oct 13, 2026
- Form 4 · Meeker David P · Sep 14, 2026
- Form 4 · Smith Hunter C · Sep 1, 2026
- Form 4 · Shulman Joseph · Aug 17, 2026
- Form 4 · Lee Jennifer Kayden · Aug 14, 2026